08:00 , Feb 13, 2012 |  BC Week In Review  |  Company News

4P Therapeutics drug delivery news

Former executives from Altea Therapeutics Corp. (Atlanta, Ga.) launched newco 4P Therapeutics. The company is partnering with pharmaceutical and medical device companies to research and develop transdermal pharmaceutical products for currently injected compounds. 4P...
08:00 , Jan 25, 2010 |  BC Week In Review  |  Company News

Altea, KAI deal

The companies will use Altea's PassPort Transdermal Delivery System to co-develop three undisclosed protein kinase C (PKC) inhibitors from KAI to treat pain, hyperparathyroidism and a potential third indication. The companies will develop the...
07:00 , Apr 6, 2009 |  BC Week In Review  |  Company News

Altea, Amylin, Eli Lilly deal

Altea granted Lilly and Amylin exclusive, worldwide rights to develop and commercialize transdermal exenatide using Altea's PassPort Transdermal Delivery System. The once daily transdermal exenatide patch is in Phase I testing for Type II diabetes....
07:00 , Apr 6, 2009 |  BioCentury  |  Finance

Ebb & Flow

Shares of Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) rode a rollercoaster last week, ultimately finishing down $2.32 (19%) to $9.68, on a mix of clinical, corporate and competitor news. On Monday, the stock was off by as much...
00:58 , Apr 2, 2009 |  BC Extra  |  Company News

Altea in exenatide patch deal with Lilly, Amylin

Altea Therapeutics Corp. (Atlanta, Ga.) granted Eli Lilly and Co. (NYSE:LLY) and Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) exclusive, worldwide rights to develop and commercialize transdermal exenatide using Altea's PassPort Transdermal Delivery System. The once daily transdermal...
07:00 , Aug 18, 2008 |  BC Week In Review  |  Company News

Altea scientific advisory board update

Altea Therapeutics Corp., Tucker, Ga.   Business: Drug delivery   Appointed: Richard Guy, professor and head of the department of pharmacy and pharmacology at the University of Bath, as chairman; Mark Prausnitz, professor at the school of...
07:00 , Jul 7, 2008 |  BC Week In Review  |  Company News

Altea, Hospira deal

Altea granted Hospira an exclusive, worldwide license to develop and commercialize an undisclosed product using Altea's PassPort transdermal delivery system. Altea will fund certain Phase I testing, and Hospira will fund development and commercialization thereafter....
08:00 , Feb 18, 2008 |  BC Week In Review  |  Company News

Altea scientific advisory board update

Altea Therapeutics Corp., Tucker, Ga.   Business: Drug delivery   Appointed: Richard Guy, professor of pharmaceutical sciences and head of the department of pharmacy and pharmacology at the University of Bath   ...
08:00 , Nov 5, 2007 |  BC Week In Review  |  Clinical News

AT2391: Phase I data

In an ongoing, open-label, U.S. Phase I trial, data from 7 evaluable patients showed that AT2391 provided steady basal levels of insulin. The transdermal patch delivering recombinant human insulin achieved therapeutic levels comparable to those...
08:00 , Feb 12, 2007 |  BC Week In Review  |  Company News

Altea board of directors update

Altea Therapeutics Corp., Tucker, Ga.   Business: Drug delivery   Appointed: William Good, an industry consultant   ...